Overview

Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This is a study to investigate the efficacy and safety of epirubicin, cisplatin and capecitabine (ECX) as neoadjuvant therapy prior to radical chemoradiotherapy using capecitabine and cisplatin as radio-sensitisers in patients with newly diagnosed localized squamous cell carcinoma of the oesophagus.

Phase:

Phase 2

Details

Lead Sponsor:

Royal Marsden NHS Foundation Trust

Treatments:

Capecitabine
Cisplatin
Epirubicin